Cargando…
Physiologically Based Pharmacokinetic Modelling of Cabozantinib to Simulate Enterohepatic Recirculation, Drug–Drug Interaction with Rifampin and Liver Impairment
Cabozantinib (CAB) is a receptor tyrosine kinase inhibitor approved for the treatment of several cancer types. Enterohepatic recirculation (EHC) of the substance is assumed but has not been further investigated yet. CAB is mainly metabolized via CYP3A4 and is susceptible for drug–drug interactions (...
Autores principales: | Gerner, Bettina, Scherf-Clavel, Oliver |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8224782/ https://www.ncbi.nlm.nih.gov/pubmed/34067429 http://dx.doi.org/10.3390/pharmaceutics13060778 |
Ejemplares similares
-
Oral antibiotics lower mycophenolate mofetil drug exposure, possibly by interfering with the enterohepatic recirculation: A case series
por: Simoons, Mirjam, et al.
Publicado: (2023) -
A Physiologically-Based Pharmacokinetic Model of Ruxolitinib and Posaconazole to Predict CYP3A4-Mediated Drug–Drug Interaction Frequently Observed in Graft versus Host Disease Patients
por: Gerner, Bettina, et al.
Publicado: (2022) -
Enterohepatic circulation of glucuronide metabolites of drugs in dog
por: Zhou, Xin, et al.
Publicado: (2019) -
Enterohepatic Circulation and Pharmacokinetics of
Genistin and Genistein in Rats
por: Yang, Ya-Yu, et al.
Publicado: (2019) -
PMON295 Investigating the ileal FXR/SHP axis in regulating lipid absorption and enterohepatic recirculation of bile acids
por: Nguyen, James, et al.
Publicado: (2022)